Symrise AG (VIE:SY1)
Austria · Delayed Price · Currency is EUR | Market Cap | 12.44B +16.8% |
| Revenue (ttm) | 4.91B -1.4% |
| Net Income | 246.08M -51.5% |
| EPS | 1.77 -51.3% |
| Shares Out | n/a |
| PE Ratio | 50.55 |
| Forward PE | 21.89 |
| Dividend | 1.25 (1.38%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | n/a |
| Open | 90.58 |
| Previous Close | 91.10 |
| Day's Range | 90.18 - 90.74 |
| 52-Week Range | 65.24 - 94.46 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Symrise AG
Symrise AG operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates in two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; sweets, chocolate, chewing gum, baked goods, cereals, ice cream, milk, yogurt and mi... [Read more]
Financial Performance
In 2025, Symrise AG's revenue was 4.93 billion, a decrease of -1.39% compared to the previous year's 5.00 billion. Earnings were 249.33 million, a decrease of -47.86%.
Financial StatementsNews
EQS-PVR: Symrise AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Symrise AG Symrise AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 16.09.2...
EQS-DD: Symrise AG: Michael Friede, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 16.09.2026 / 11:46 CET/CEST The issuer is solely responsi...
EQS-DD: Symrise AG: Walter Ribeiro, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 16.09.2026 / 09:05 CET/CEST The issuer is solely responsi...
Symrise Q2 Earnings Call Highlights
Symrise ETR: SY1 reported first-half 2026 sales of €2.539 billion and organic growth of 2%, as a stronger second quarter offset a slight organic sales decline in the first quarter. The flavor and frag...
Symrise AG Earnings Call Transcript: Q2 2026
H1 2026 saw 2% organic sales growth to €2.539 billion, with Q2 momentum and strong cash generation. Adjusted EBITDA margin was 21.8%, slightly below last year due to reinvestment and higher costs, but cash flow and financial flexibility improved. Guidance for 2026 is reaffirmed, supported by robust project pipelines and ongoing transformation.
Symrise AG Quarterly report: Q2 2026
Symrise AG has published its Q2 2026 quarterly earnings report on July 30, 2026.
Symrise AG Earnings release: Q2 2026
Symrise AG released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Symrise AG Slides: Q2 2026
Symrise AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Symrise AG Earnings Call Transcript: Q1 2026
Q1 2026 saw a slight organic sales decline but outperformed expectations, with strong growth in key segments and regions offsetting EMEA and Scent & Care weakness. Full-year guidance is reaffirmed, with sequential improvement and margin expansion expected.
Symrise AG Earnings release: Q1 2026
Symrise AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Symrise AG Slides: Q1 2026
Symrise AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Symrise AG Earnings Call Transcript: Q4 2025
2025 saw resilient organic growth, record profitability, and strong cash flow despite FX and market headwinds. Strategic transformation, portfolio optimization, and efficiency gains drove margin expansion, while 2026 guidance remains prudent amid macro uncertainty, with growth expected to accelerate in H2.
Symrise AG Annual report: Q4 2025
Symrise AG has published its Q4 2025 annual report on March 4, 2026.
Symrise AG Earnings release: Q4 2025
Symrise AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Symrise AG Slides: Q4 2025
Symrise AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Symrise AG Earnings release: Q4 2025
Symrise AG released its Q4 2025 earnings on March 4, 2026, summarizing the period's financial results.
Symrise AG Slides: Q4 2025
Symrise AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 4, 2026.
Symrise AG Earnings Call Transcript: Q3 2025
Q3 2025 saw 1.4% organic sales growth, with strong performance in EMEA and food & beverage, but softness in North America and Latin America. Full-year growth guidance was lowered to 2.3%-3.3% amid macro headwinds, while cost savings and margin targets remain on track.
Symrise AG Earnings release: Q3 2025
Symrise AG released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
Symrise AG Slides: Q3 2025
Symrise AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Symrise and Aplantex Confirm an Agreement to Establish a Partnership
MONTREAL--(BUSINESS WIRE)--Symrise AG ("Symrise") and Aplantex Bio ("Aplantex") agree on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules ...
Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...